Publicaciones en colaboración con investigadores/as de Hospital Miguel Servet (9)

2024

  1. Immunoparesis recovery in newly diagnosed transplant ineligible multiple myeloma patients, an independent prognostic factor that complements minimal residual disease

    Annals of Hematology

2022

  1. Lenalidomide-dexamethasone versus observation in high-risk smoldering myeloma after 12 years of median follow-up time: A randomized, open-label study

    European Journal of Cancer, Vol. 174, pp. 243-250

  2. Single versus tandem autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma and high-risk cytogenetics. A retrospective, open-label study of the PETHEMA/Spanish Myeloma Group (GEM)

    Leukemia and Lymphoma, Vol. 63, Núm. 14, pp. 3438-3447

2016

  1. Immune status of high-risk smoldering multiple myeloma patients and its therapeutic modulation under lendex: A longitudinal analysis

    Blood, Vol. 127, Núm. 9, pp. 1151-1162

  2. Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial

    The Lancet Oncology, Vol. 17, Núm. 8, pp. 1127-1136

2013

  1. Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma

    New England Journal of Medicine, Vol. 369, Núm. 5, pp. 438-447

2012

  1. Myelodysplasia-associated immunophenotypic alterations of bone marrow cells in myeloma: Are they present at diagnosis or are they induced by lenalidomide?

    Haematologica, Vol. 97, Núm. 10, pp. 1608-1611

  2. SNP-based mapping arrays reveal high genomic complexity in monoclonal gammopathies, from MGUS to myeloma status

    Leukemia, Vol. 26, Núm. 12, pp. 2521-2529

2011

  1. Lenalidomide is effective as salvage therapy in refractory or relapsed multiple myeloma: Analysis of the Spanish compassionate use registry in advanced patients

    International Journal of Hematology, Vol. 93, Núm. 3, pp. 351-360